Systems pharmacology: Bridging systems biology and Pharmacokinetics- Pharmacodynamics (PKPD) in drug discovery and development

Pharmaceutical Research

Volumn 28, Issue 7, 2011, Pages 1460-1464

  Van Der Graaf, Piet H ^a   Benson, Neil ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

modelling and simulation; pharmacokinetics pharmacodynamics; PKPD; systems biology; systems pharmacology

Indexed keywords

IMMUNOGLOBULIN E; MONOCLONAL ANTIBODY; OMALIZUMAB;

DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG POTENCY; DRUG RESEARCH; EXPERIMENTATION; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PRODUCTIVITY; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; SIMULATION; TRANSLATIONAL RESEARCH;

COMPUTER SIMULATION; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHARMACOLOGY; SYSTEMS BIOLOGY;

EID: 79959900575     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0467-9     Document Type: Review

References (26)

1. L Zhang M Pfister B Meibohm 2008 Concepts and challenges in quantitative pharmacology and model-based drug development AAPS J 10 552 9 19003542 10.1208/s12248-008-9062-3 1:CAS:528:DC%2BD1MXltVSls7w%3D
2. JVS Gobburu LJ Lesko 2009 Quantitative disease, drug and trial models Ann Rev Pharmacol Toxicol 49 291 301 10.1146/annurev.pharmtox.011008.145613 1:CAS:528:DC%2BD1MXisV2jsb8%3D
3. Williams PJ, Ette EI. Pharmacometrics-impacting drug development and pharmacotherapy. In: Ette EI, Williams PJ, editors. Pharmacometrics-The science of quantitative pharmacology. Hoboken: Wiley; 2007. p. 1-21.
4. Danhof M, Van der Graaf PH, Jonker DM, Visser SAG, Zuideveld KP. Mechanism-based pharmacokinetic-pharmacodynamic modeling for the prediction of in vivo drug concentration-effect relationships-application in drug candidate selection and lead optimization. In: Testa B, Van de Waterbeemd H (eds) Comprehensive Medicinal Chemistry II (Part 5). Elsevier; 2007. p. 885-908.
5. BA Ploeger PH Van der Graaf M Danhof 2009 Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling Drug Metab Pharmacokinet 24 3 15 19252332 10.2133/dmpk.24.3 1:CAS:528:DC%2BD1MXks1Whu74%3D
6. DE Mager S Woo WJ Jusko 2009 Scaling pharmacodynamics from in vitro and preclinical animal studies to humans Drug Metab Pharmacokinet 24 16 24 19252333 10.2133/dmpk.24.16 1:CAS:528:DC%2BD1MXks1Whu78%3D
7. PH Van der Graaf J Gabrielsson 2009 Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development Future Med Chem 1 1371 4 10.4155/fmc.09.124
8. J Gabrielsson AR Green PH Van Der Graaf 2010 Optimising in vivo pharmacology studies-Practical PKPD considerations J Pharmacol Toxicol Methods 61 146 56 20153442 10.1016/j.vascn.2010.02.002 1:CAS:528:DC%2BC3cXksVeitb0%3D
9. I Kola J Landis 2004 Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 711 5 15286737 10.1038/nrd1470 1:CAS:528: DC%2BD2cXmtVOhtLs%3D (Pubitemid 39173511)
10. B Munos 2009 Lessons from 60 years of pharmaceutical innovation Nat Rev Drug Discov 8 959 68 19949401 10.1038/nrd2961 1:CAS:528:DC%2BD1MXhsV2gtrbK
11. J Gabrielsson O Fjellstrom J Ulander M Rowley PH Van Der Graaf 2011 Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry Curr Top Med Chem 11 404 18 21320067 10.2174/156802611794480864 1:CAS:528:DC%2BC3MXkslSnurw%3D
12. BM Agoram SW Martin PH Van der Graaf 2007 The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics Drug Discov Today 12 1018 24 18061880 10.1016/j.drudis.2007.10.002 1:CAS:528:DC%2BD2sXhsVSmurnO (Pubitemid 350180561)
13. TP Kenakin 2009 Cellular assays as portals to seven-transmembrane receptor-based drug discovery Nat Rev Drug Discov 8 617 26 19609267 10.1038/nrd2838 1:CAS:528:DC%2BD1MXos1Wrsb4%3D
14. G Langdon JD Davis LM McFadyen M Dewhurst NS Brunton JK Rawal, et al. 2010 Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent Br J Clin Pharmacol 69 336 45 20406218 10.1111/j.1365-2125.2009.03594.x 1:CAS:528:DC%2BC3cXltl2qur8%3D
15. JM Berg ME Rogers PM Lyster 2010 Systems Biology and Pharmacology Clin Pharmacol Ther 88 17 9 20562889 10.1038/clpt.2010.69 1:STN:280: DC%2BC3crhslChtw%3D%3D
16. Quantitative and Systems Pharmacology Workshop II: http://meetings.nigms. nih.gov/index.cfm?event=home&ID=8316
17. ON Jensen 2004 Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry Curr Opin Chem Biol 8 33 41 15036154 10.1016/j.cbpa.2003.12.009 (Pubitemid 38201475)
18. HB Van der Worp DW Howells ES Sena MJ Porritt S Rewell V O'Collins, et al. 2010 Can animal models of disease reliably inform human studies? PLoS Med 7 1 8
19. P Kohl EJ Crampin TA Quinn D Noble 2010 Systems biology: an approach Clin Pharmacol Ther 88 25 33 20531468 10.1038/clpt.2010.92 1:STN:280: DC%2BC3crhs1ehuw%3D%3D
20. M Swat SM Kielbasa S Polak B Olivier FJ Bruggeman M Quinton Tulloch, et al. 2011 What it takes to understand and cure a living system: computational systems biology and systems biology-driven pharmacokinetics-pharmacodynamics platform Interface Focus 1 16 23
21. A Cohen 2008 Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development-designing informative human pharmacological studies Clin Pharmacokin 47 373 81 10.2165/00003088-200847060-00002 1:CAS:528:DC%2BD1cXos1ehsr0%3D (Pubitemid 351685387)
22. Systems biology: a vision for engineering and medicine. A report from the Academy of Medical Sciences and The Royal Academy of Engineering (2007). http://raeng.org.uk/policy/engagement/pdf/systems-biology-report.pdf.
23. M Danhof G Alvan SG Dahl J Kuhlmann G Paintaud 2005 Mechanism-based pharmacokinetic-pharmacodynamic modelling-a new classification of biomarkers Pharm Res 22 1432 7 16132354 10.1007/s11095-005-5882-3 1:CAS:528: DC%2BD2MXptVWltbc%3D (Pubitemid 41215882)
24. Aston PJ, Derks G, Raji A, Agoram BA, Van Der Graaf PH. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol. 2011. doi: 10.1016/j.jtbi.2011.04.030.
25. WS Putnam J Li J Haggstrom C Ng S Kadkhodayan-Fischer M Cheu, et al. 2008 Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody AAPS J 10 425 30 18686041 10.1208/s12248-008-9045-4 1:CAS:528:DC%2BD1cXhtlOgsbnM
26. Van Der Graaf PH. Biomarkers and Biomeasures: key enablers for translational PK/PD in drug discovery and development. Keynote lecture at The Joint Pharmaceutical Analysis Group (JPAG) Biomarkers 2011 Workshop, London 2011, http://www.pjonline.com/meeting/biomarkers2011.